The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Open accessAbstract
Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.Methods KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031.Findings Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis. Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis. At final analysis, grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of 287 in the cetuximab with chemotherapy group. Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.Interpretation Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.Funding Merck Sharp & Dohme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of two fatal cases of myocarditis showed overexpression of cardiac proteins in the tumors of the affected patients, also potentially suggesting an overlap.18”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737
Self-citationHead and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S. S., Adelstein, D. J., Adkins, D. R., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,377
Self-citationThe Efficiency of Cox's Likelihood Function for Censored Data
Efron, B. (1977) · Journal of the American Statistical Association · doi:10.1080/01621459.1977.10480613 · Cited by 1,240
Cited by
Sorted by citations
Items 401–500 of 1,002
Haider, S. P., Sharaf, K., Zeevi, T., Baumeister, P., Reichel, C. A., Forghani, R., Kann, B. H., Petukhova, A., Judson, B. L., Prasad, M. L., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100906 · Cited by 37
Self-citationEvrard, D., Hourseau, M., Couvelard, A., Paradis, V., Gauthier, H., Raymond, É., Halimi, C., Barry, B., & Faivre, S. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1844403 · Cited by 37
Kulasinghe, A., Taheri, T., O'Byrne, K. J., Hughes, B. G. M., Kenny, L., & Punyadeera, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607349 · Cited by 37
Self-citationImmune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
Veigas, F., Mahmoud, Y. D., Merlo, J. P., Rinflerch, A., Rabinovich, G. A., & Girotti, M. R. (2021) · Cancers · doi:10.3390/cancers13051018 · Cited by 41
Tomioka, H., Yamagata, Y., Oikawa, Y., Ohsako, T., Kugimoto, T., Kuroshima, T., Hirai, H., Shimamoto, H., & Harada, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-84704-w · Cited by 37
Huang, Z., Su, Q., Li, W., Ren, H., Huang, H., & Wang, A. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.06.014 · Cited by 37
Misztal, C. I., Green, C., Mei, C., Bhatia, R. G., Torres, J. M. V., Kamrava, B., Moon, S. Y., Nicolli, E. A., Weed, D. T., Sargi, Z., et al. (2021) · Cancers · doi:10.3390/cancers13236011 · Cited by 36
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, A., D’Alessio, A., Enica, A., TALBOT, T. L., Fulgenzi, C. A. M., Nteliopoulos, G., Goldin, R. D., Cortellini, A., & Pinato, D. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049244 · Cited by 35
Benecke, L., Chiang, D. M., Ebnöther, E., Pfaffl, M. W., & Müller, L. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5423 · Cited by 38
Hagege, A., Saâda-Bouzid, E., Ambrosetti, D., Rastoin, O., Boyer, J., He, X., Rousset, J., Montemagno, C., Doyen, J., Pédeutour, F., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100659 · Cited by 37
Artificial intelligence in head and neck cancer diagnosis
Bassani, S., Santonicco, N., Eccher, A., Scarpa, A., Vianini, M., Brunelli, M., Bisi, N., Nocini, R., Sacchetto, L., Munari, E., et al. (2022) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2022.100153 · Cited by 40
Chen, Y., Ding, X., Bai, X., Zhou, Z., Liu, Y., Zhang, X., Yu, J., & Hu, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110329 · Cited by 37
Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1
Seiwert, T. Y., & Kiess, A. P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02046 · Cited by 37
Shi, Y., Xie, T., Leach, D. G., Wang, B., Young, S. W., Osman, A. A., Sikora, A. G., Ren, X., Hartgerink, J. D., Myers, J. N., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0607 · Cited by 36
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
Coleman, N., Marcelo, K. L., Hopkins, J. F., Khan, N., Du, R. R., Hong, L., Park, E., Balsara, B., Leoni, M., Pickering, C. R., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00211 · Cited by 36
Smussi, D., Mattavelli, D., Paderno, A., Gurizzan, C., Lorini, L., Romani, C., Bignotti, E., Grammatica, A., Ravanelli, M., & Bossi, P. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102644 · Cited by 38
Shi, Y., Guo, W., Wang, W., Wu, Y., Fang, M., Huang, X., Han, P., Zhang, Q., Pin, D., Zhou, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03110-7 · Cited by 36
Self-citationSilver, N. L., Dai, J., Kerr, T. D., Altemus, J. B., Garg, R. R., Simmons, H. L., Alban, T. J., Noël‐Romas, L., Makarov, V., Shih, D. J. H., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01067-1 · Cited by 42
Translating KEYNOTE-048 into practice recommendations for head and neck cancer
Szturz, P., & Vermorken, J. B. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.164 · Cited by 36
Iannelli, F., Zotti, A. I., Roca, M. S., Grumetti, L., Lombardi, R., Moccia, T., Vitagliano, C., Milone, M. R., Ciardiello, C., Bruzzese, F., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00732 · Cited by 36
Blockade of epidermal growth factor and its receptor and axial elongation in experimental myopia
Dong, L., Shi, X., Li, Y. F., Jiang, X., Wang, Y. X., Lan, Y. J., Wu, H. T., Jonas, J. B., & Wei, W. B. (2020) · The FASEB Journal · doi:10.1096/fj.202001095rr · Cited by 36
Pan, H., Wang, X., Huang, W., Dai, Y., Yang, M. Y., Liang, H., Wu, X., Zhang, L., Huang, W., Lü, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.557157 · Cited by 36
Self-citationNishikawa, D., Suzuki, H., Beppu, S., Terada, H., Sawabe, M., Kadowaki, S., Sone, M., & Hanai, N. (2020) · Cancer Science · doi:10.1111/cas.14706 · Cited by 38
Self-citationKrasniqi, E., Barba, M., Venuti, A., Pizzuti, L., Cappuzzo, F., Landi, L. M., Carpano, S., Marchetti, P., Villa, A., Vizza, E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071525 · Cited by 39
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
Fundytus, A. M., Booth, C. M., & Tannock, I. F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.208 · Cited by 36
Burcher, K. M., Lantz, J. W., Gavrila, E., Abreu, A., Burcher, J. T., Faucheux, A. T., Xie, A., Jackson, C. W., Song, A. H., Hughes, R. T., et al. (2021) · Cancers · doi:10.3390/cancers13225733 · Cited by 40
The role of partial-EMT in the progression of head and neck squamous cell carcinoma
Kisoda, S., Mouri, Y., Kitamura, N., Yamamoto, T., Miyoshi, K., & Kudo, Y. (2022) · Journal of Oral Biosciences · doi:10.1016/j.job.2022.02.004 · Cited by 36
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
Miserocchi, G., Spadazzi, C., Calpona, S., Rosa, F. D., Usai, A., Vita, A. D., Liverani, C., Cocchi, C., Vanni, S., Calabrese, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060854 · Cited by 36
Florez, M. A., Kemnade, J. O., Chen, N., Du, W., Sabichi, A. L., Wang, D. Y., Huang, Q., Miller-Chism, C. N., Jotwani, A. C., Chen, A. C., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0143 · Cited by 37
Melo-Alvim, C., Neves, M. E., Santos, J. L., Abrunhosa-Branquinho, A. N., Barroso, T., Costa, L., & Ribeiro, L. (2022) · Diagnostics · doi:10.3390/diagnostics13010099 · Cited by 35
CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
Ciulean, I. S., Fischer, J., Quaiser, A., Bach, C. T., Abken, H., Tretbar, S., Fricke, S., Koehl, U., Schmiedel, D., & Grünwald, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290488 · Cited by 35
Sadeghirad, H., Monkman, J. H., Tan, C. W., Liu, N., Yunis, J., Donovan, M. L., Moradi, A., Jhaveri, N., Perry, C., Adams, M. N., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05409-y · Cited by 35
Self-citationLiu, H., Xiong, X., Yu, Z., Shao, Z., Chen, G., Liu, Y.-T., Wang, X., Fu, Q.-Y., Cheng, X., Li, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101930 · Cited by 35
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
dos Santos, L. V., Abrahão, C. M., & William, W. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596290 · Cited by 36
Self-citationImmunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Hsieh, R. W., Borson, S., Tsagianni, A., & Zandberg, D. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705614 · Cited by 35
Liu, L., Liu, F., Liu, D., Yuan, W., Zhang, M., Wei, P., & Yi, T. (2022) · Angewandte Chemie · doi:10.1002/ange.202116807 · Cited by 34
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
Song, Q., Ye, Y., Jiang, D., Qin, Z., Xu, C., Wang, H., Huang, J., Chen, L., Luo, R., Zhang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31719-0 · Cited by 35
Self-citationSmith, A. E., Chan, S., Wang, Z., McCloskey, A., Reilly, Q., Wang, J. Z., Patel, H. V., Koshizuka, K., Soifer, H. S., Kessler, L. V., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0282 · Cited by 35
Self-citationRosenberg, A. J., Juloori, A., Jelinek, M. J., Agrawal, N., Cursio, J., Cipriani, N. A., Lingen, M. W., Izumchenko, E., Katipally, R. R., Chin, J., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.0081 · Cited by 36
Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects
Rajendra, A., Noronha, V., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1708197 · Cited by 34
Vivaldi, C., Catanese, S., Massa, V., Pecora, I., Salani, F., Santi, S., Lencioni, M., Vasile, E., Falcone, A., & Fornaro, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051658 · Cited by 34
Girolami, I., Pantanowitz, L., Munari, E., Martini, M., Nocini, R., Bisi, N., Molteni, G., Marchioni, D., Ghimenton, C., Brunelli, M., et al. (2020) · Head & Neck · doi:10.1002/hed.26339 · Cited by 34
Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry
Ahn, J., Jin, M., Song, E., Ryu, Y., Song, D. E., Kim, S., Kim, T. Y., Kim, W. B., Shong, Y. K., Jeon, M. J., et al. (2020) · Thyroid · doi:10.1089/thy.2020.0312 · Cited by 34
Karabajakian, A., Bouaoud, J., Michon, L., Kamal, M. T., Crozes, C., Zrounba, P., Auclair, J., Gadot, N., Attignon, V., Tourneau, C. L., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105368 · Cited by 34
Zouein, J., Kesrouani, C., & Kourié, H. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0336 · Cited by 37
Pembrolizumab in the first-line treatment of advanced head and neck cancer
de Sousa, L. G., & Ferrarotto, R. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1996228 · Cited by 34
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Ferris, R. L., Moskovitz, J. M., Kunning, S. R., Ruffin, A. T., Reeder, C., Ohr, J. P., Gooding, W. E., Kim, S., Karlovits, B. J., Vignali, D. A. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0426 · Cited by 34
Self-citationLiu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 36
Mainguené, J., Vacher, S., Kamal, M. T., Hamza, A., Masliah‐Planchon, J., Baulande, S., Ibadioune, S., Borcoman, É., Cacheux, W., Calugaru, V., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13219 · Cited by 34
Nenclares, P., Rullan, A., Tam, K., Dunn, L. A., John, M. A. S., & Harrington, K. J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351336 · Cited by 38
Self-citationAdvances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review
Yu, C., Li, L., Wang, S., Xu, Y., Wang, L., Huang, Y., Hieawy, A., Liu, H., & Ma, J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.010 · Cited by 34
Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma
Siqueira, J. M., Heguedusch, D., Rodini, C. O., Nunes, F. D., & Rodrigues, M. F. S. D. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.107 · Cited by 33
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients
Taylor, K., Zou, J., Magalhães, M. A. F., Oliva, M., Spreafico, A., Hansen, A. R., McDade, S. S., Coyle, V. M., Lawler, M., Elimova, E. C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.014 · Cited by 33
Self-citationLi, M., Sun, D., Song, N., Chen, X., Zhang, X., Zheng, W., Yu, Y., & Han, C. (2023) · Oncology Reports · doi:10.3892/or.2023.8599 · Cited by 42
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
Wang, C.-W., Biswas, P. K., Islam, A., Chen, M., & Chueh, P. J. (2024) · Cells · doi:10.3390/cells13050413 · Cited by 35
Wuerdemann, N., Gültekin, S. E., Pütz, K., Wittekindt, C., Huebbers, C. U., Sharma, S. J., Eckel, H. N. C., Schubotz, A. B., Gattenlöhner, S., Büttner, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155228 · Cited by 33
Chandra, J., Woo, W.-P., Finlayson, N., Liu, H. Y.-H., McGrath, M. L., Ladwa, R., Brauer, M., Xu, Y., Hanson, S. J., Panizza, B. J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02720-7 · Cited by 33
FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition
Diab, A., Gem, H., Swanger, J., Kim, H. Y., Smith, K., Zou, G., Raju, S. C., Kao, M. C., Fitzgibbon, M., Loeb, K. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013921117 · Cited by 33
Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
Kordbacheh, F., & Farah, C. S. (2021) · Cancers · doi:10.3390/cancers13215471 · Cited by 34
Xing, D. T., Khor, R., Gan, H. K., Wada, M., Ermongkonchai, T., & Ng, S. P. (2021) · Cancers · doi:10.3390/cancers13225716 · Cited by 33
Self-citationVaccine-Based Immunotherapy for Head and Neck Cancers
Beyaert, S. P., Machiels, J., & Schmitz, S. (2021) · Cancers · doi:10.3390/cancers13236041 · Cited by 32
Taylor, M. H., Betts, C. B., Maloney, L. T., Nadler, E., Algazi, A. P., Guarino, M. J., Nemunaitis, J. J., Jimeno, A., Patel, P., Munugalavadla, V., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2547 · Cited by 33
Self-citationCabezas-Camarero, S., & Pérez‐Segura, P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103569 · Cited by 33
Oligometastatic Head and Neck Cancer: Challenges and Perspectives
Bahig, H., Huang, S. H., & O’Sullivan, B. (2022) · Cancers · doi:10.3390/cancers14163894 · Cited by 33
Mao, L., Zhou, J., Xiao, Y., Yang, Q., Yang, S., Wang, S., Wu, Z., Xiong, H., Yu, H., & Sun, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02230-0 · Cited by 34
Bozec, A., Poissonnet, G., Dassonville, O., & Culié, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031237 · Cited by 32
Nigam, N., Bernard, B., Sevilla, S., Kim, S., Dar, M. S., Tsai, D., Robbins, Y. L., Burkitt, K., Sievers, C. M., Allen, C. T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112823 · Cited by 37
Xing, A., Lv, D., Wu, C., Zhou, K., Zhao, T., Zhao, L., Wang, H., & Feng, H. (2024) · Current Genomics · doi:10.2174/0113892029278082240118053857 · Cited by 33
Self-citationMeci, A., Goyal, N., & Slonimsky, G. (2024) · Cancers · doi:10.3390/cancers16040703 · Cited by 35
Li, K., Zhang, C., Zhou, R., Cheng, M., Ling, R., Xiong, G., Ma, J., Zhu, Y., Chen, S., Chen, J., et al. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00292-1 · Cited by 34
Talapko, J., Erić, S., Meštrović, T., Mravak‐Stipetić, M., Juzbašić, M., Katalinić, D., Bekić, S., Muršić, D., Flam, J., Belić, D., et al. (2024) · Cancers · doi:10.3390/cancers16172997 · Cited by 32
den Bossche, V. V., Vignau, J., Vigneron, E., Rizzi, I., Zaryouh, H., Wouters, A., Ambroise, J., Laere, S. V., Beyaert, S. P., Helaers, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56675-3 · Cited by 37
Zhang, J., Choi, H., Kim, Y., Park, J., Cho, S., Kim, E., Cho, A., Lee, J. Y., Choi, J., Low, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011346 · Cited by 34
Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. P. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104554 · Cited by 32
Kacew, A. J., Harris, E. J., Lorch, J. H., Schoenfeld, J. D., Margalit, D. N., Kass, J. I., Tishler, R. B., Haddad, R. I., & Hanna, G. J. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104676 · Cited by 32
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
McCusker, M. G., Orkoulas-Razis, D., & Mehra, R. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s196252 · Cited by 31
Puntigam, L. K., Jeske, S. S., Götz, M., Greiner, J., Laban, S. A., Theodoraki, M., Doescher, J., Weissinger, S. E., Brunner, C., Hoffmann, T. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155181 · Cited by 34
Self-citationEfficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria
Swiecicki, P. L., Bellile, E. L., Brummel, C. V., Brenner, J. C., & Worden, F. P. (2020) · Cancer · doi:10.1002/cncr.33226 · Cited by 32
AKT3 Is a Novel Regulator of Cancer-Associated Fibroblasts in Head and Neck Squamous Cell Carcinoma
Takahashi, H., Rokudai, S., Kawabata‐Iwakawa, R., Sakakura, K., Oyama, T., Nishiyama, M., & Chikamatsu, K. (2021) · Cancers · doi:10.3390/cancers13061233 · Cited by 32
Hirshoren, N., Al-kharouf, I., Weinberger, J. M., Eliashar, R., Popovtzer, A., Knaanie, A., Fellig, Y., Neuman, T., Meir, K. S., Maly, A., et al. (2021) · Oncology · doi:10.1159/000515441 · Cited by 32
Self-citationBouchereau, S., Chaplain, L., Fort, M., Beauchet, A., Sidibé, T., Chapalain, M., González‐Lara, L., Longvert, C., Blom, A., Saïag, P., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01486-8 · Cited by 33
Hongo, T., Yamamoto, H., Jiromaru, R., Yasumatsu, R., Kuga, R., Nozaki, Y., Hashimoto, K., Matsuo, M., Wakasaki, T., Tamae, A., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00868-w · Cited by 33
Self-citationAffolter, A., Lammert, A., Kern, J., Scherl, C., & Rotter, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666515 · Cited by 34
Wusiman, D., Guo, L., Huang, Z., Li, Z., Liu, S., Ying, J., Li, W., & An, C. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153934 · Cited by 35
Nuti, S. L., Zhang, Y., Zerrouki, N., Roach, C. M., Bänfer, G., Kumar, G., Manna, E. A., Diezko, R., Kersch, K., Rüschoff, J., et al. (2022) · Histopathology · doi:10.1111/his.14775 · Cited by 32
Self-citationChemoprevention of oral cancer: A review and future perspectives
Liao, Y., Chou, W., Chang, C., Lin, M., Wang, C., Lou, P., & Chen, T. (2023) · Head & Neck · doi:10.1002/hed.27301 · Cited by 32
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Muijlwijk, T., Nijenhuis, D., Ganzevles, S., Brink, A., Ke, C.-L., Fass, J. N., Rajamanickam, V., Leemans, C., Koguchi, Y., Fox, B. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007573 · Cited by 34
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 39
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Saini, K. S., Somara, S., Ko, H. C., Thatai, P., Quintana, A., Wallen, Z. D., Green, M. F., Mehrotra, R., McGuigan, S., Pang, L., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1473706 · Cited by 31
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma
Lee, A. M., Weaver, A. N., Acosta, P., Harris, L., & Bowles, D. W. (2024) · Cancers · doi:10.3390/cancers16203488 · Cited by 31
Li, C., Qi, X., & Yan, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572195 · Cited by 31
Shebbo, S., Alateyah, N., Yassin, E., Mahmoud, D. E. S., Tamimi, F., Anweigi, L. M., Elhissi, A. M. A., Abou-Saleh, H., Elrayess, M. A., & Agouni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626243 · Cited by 41
Patil, V., Noronha, V., Joshi, A., Abhyankar, A. V., Menon, N. S., Dhumal, S. B., & Prabhash, K. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104673 · Cited by 31
Current Management and Progress in Radiotherapy for Small Cell Lung Cancer
Tjong, M. C., Mak, D. Y., Shahi, J., Li, G., Chen, H., & Louie, A. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01146 · Cited by 31
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker
Emancipator, K. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00525-1 · Cited by 31
Chen, S., Huang, W., Kao, W., Hsiao, S., Pan, H.-Y., Fang, C.-W., Shiue, Y., Chou, C.-L., & Li, C. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00699-y · Cited by 33
Goggi, J., Hartimath, S. V., Xuan, T. Y., Khanapur, S., Jieu, B., Chin, H. X., Ramasamy, B., Cheng, P. K. C., Rong, T. J., Yong, F., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01596-y · Cited by 31
Metadata
- Authors
- Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R.-L., González Mendoza, R., Roy, A., Zhang, Y., Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D., Lerzo, G., Tatangelo, M., Varela, M., Zarba, J. J., Boyer, M., Gan, H., Gao, B., Hughes, B., Mallesara, G., Rischin, D., Taylor, A., Burian, M., Fuereder, T., Greil, R., Barrios, C. H., de Castro Junior, D. O., Castro, G., Franke, F. A., Girotto, G., Lima, I. P. F., Nicolau, U. R., Pinto, G. D. J., Santos, L., Victorino, A.-P., Chua, N., Couture, F., Gregg, R., Hansen, A., Hilton, J., McCarthy, J., Soulieres, D., Ascui, R., Gonzalez, P., Villanueva, L., Torregroza, M., Zambrano, A., Holeckova, P., Kral, Z., Melichar, B., Prausova, J., Vosmik, M., Andersen, M., Gyldenkerne, N., Jurgens, H., Putnik, K., Reinikainen, P., Gruenwald, V., Laban, S., Aravantinos, G., Boukovinas, I., Georgoulias, V., Psyrri, A., Kwong, D., Al-Farhat, Y., Csoszi, T., Erfan, J., Horvai, G., Landherr, L., Remenar, E., Ruzsa, A., Szota, J., Billan, S., Gluck, I., Gutfeld, O., Popovtzer, A., Benasso, M., Bui, S., Ferrari, V., Licitra, L., Nole, F., Fujii, T., Fujimoto, Y., Hanai, N., Hara, H., Matsumoto, K., Mitsugi, K., Monden, N., Nakayama, M., Okami, K., Oridate, N., Shiga, K., Shimizu, Y., Sugasawa, M., Tahara, M., Takahashi, M., Takahashi, S., Tanaka, K., Ueda, T., Yamaguchi, H., Yamazaki, T., Yasumatsu, R., Yokota, T., Yoshizaki, T., Kudaba, I., Stara, Z., Wan Ishak, W. Z., Cheah, S. K., Aguilar Ponce, J., Gonzalez Mendoza, R., Hernandez Hernandez, C., Medina Soto, F., Buter, J., Hoeben, A., Oosting, S., Suijkerbuijk, K., Bratland, A., Brydoey, M., Alvarez, R., Mas, L., Caguioa, P., Querol, J., Regala, E. E., Tamayo, M. B., Villegas, E. M., Kawecki, A., Karpenko, A., Klochikhin, A., Smolin, A., Zarubenkov, O., Goh, B. C., Cohen, G., du Toit, J., Jordaan, C., Landers, G., Ruff, P., Szpak, W., Tabane, N., Brana, I., Iglesias Docampo, L., Lavernia, J., Mesia, R., Abel, E., Muratidu, V., Nielsen, N., Cristina, V., Rordorf, T., Rothschild, S., Hong, R.-L., Wang, H.-M., Yang, M.-H., Yeh, S.-P., Yen, C.-J., Ngamphaiboon, N., Soparattanapaisarn, N., Sriuranpong, V., Aksoy, S., Cicin, I., Ekenel, M., Harputluoglu, H., Ozyilkan, O., Harrington, K., Agarwala, S., Ali, H., Alter, R., Anderson, D., Bruce, J., Burtness, B., Campbell, N., Conde, M., Deeken, J., Edenfield, W., Feldman, L., Gaughan, E., Goueli, B., Halmos, B., Hegde, U., Hunis, B., Jotte, R., Karnad, A., Khan, S., Laudi, N., Laux, D., Martincic, D., McCune, S., McGaughey, D., Misiukiewicz, K., Mulford, D., Nadler, E., Neupane, P., Nunnink, J., Ohr, J., O'Malley, M., Patson, B., Paul, D., Popa, E., Powell, S., Redman, R., Rella, V., Rocha Lima, C., Sivapiragasam, A., Su, Y., Sukari, A., Wong, S., Yilmaz, E., & Yorio, J.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Oslo University Hospital (NO)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mahidol University (TH)
- Paracelsus Medical University (AT)
- National Cancer Center Hospital East (JP)
- The University of Melbourne (AU)
- Autonomous University of Chihuahua (MX)
- ORCID
- Basté, Neus
- Bratland, Åse
- Roy, Ananya
- Jin, Fan
- Boyer, Michael
- Gan, Hui
- Gao, Bo
- Mallesara, Girish
- Burian, Martin
- Barrios, Carlos Henrique
- Franke, Fabio Andre
- Girotto, Gustavo
- Nicolau, Ulisses Ribaldo
- Pinto, Gustavo Dix Junqueira
- Santos, Lucas
- Victorino, Ana-Paula
- Chua, Neil
- Gregg, Richard
- Hansen, Aaron
- Hilton, John
- Zambrano, Angela
- Melichar, Bohuslav
- Andersen, Maria
- Reinikainen, Petri
- Laban, Simon
- Aravantinos, Gerasimos
- Boukovinas, Ioannis
- Billan, Salem
- Popovtzer, Aron
- Bui, Simona
- Licitra, Lisa
- Fujii, Takashi
- Fujimoto, Yasushi
- Hanai, Nobuhiro
- Hara, Hiroki
- Matsumoto, Koji
- Monden, Nobuya
- Nakayama, Masahiro
- Okami, Kenji
- Oridate, Nobuhiko
- Shiga, Kiyoto
- Shimizu, Yasushi
- Sugasawa, Masashi
- Takahashi, Masanobu
- Takahashi, Shunji
- Tanaka, Kaoru
- Ueda, Tsutomu
- Yamaguchi, Hironori
- Yamazaki, Tomoko
- Yasumatsu, Ryuji
- Yokota, Tomoya
- Yoshizaki, Tomokazu
- Buter, Jan
- Hoeben, Ann
- Oosting, S.
- Suijkerbuijk, Karijn
- Mas, Luis
- Caguioa, Priscilla
- Kawecki, Andrzej
- Klochikhin, Arkadiy
- Smolin, Alexey
- Goh, Boon Cher
- Cohen, Graham
- Ruff, Paul
- Szpak, Waldemar
- Lavernia, Javier
- Abel, Edvard
- Rothschild, Sacha
- Wang, Hung-Ming
- Yang, Muh-Hwa
- Yeh, Su-Peng
- Yen, Chia-Jui
- Sriuranpong, Virote
- Aksoy, Sercan
- Ekenel, Meltem
- Agarwala, Sanjiv
- Ali, Haythem
- Alter, Robert
- Anderson, Daniel
- Bruce, Justine
- Campbell, Nicholas
- Conde, Miguel
- Deeken, John
- Feldman, Lawrence
- Gaughan, Elizabeth
- Hegde, Upendra
- Jotte, Robert
- Karnad, Anand
- Khan, Saad
- Laudi, Noel
- Laux, Douglas
- McCune, Steven
- Misiukiewicz, Krzysztof
- Nadler, Eric
- Ohr, James
- Paul, Doru
- Powell, Steven
- Sivapiragasam, Abirami
- Sukari, Ammar
- Wong, Stuart
- Yilmaz, Emrullah
- Yorio, Jeffrey
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 394
- Issue
- 10212
- Pages
- 1915-1928
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2986633517
- Cited by
- 3,336
- References
- 25
- Citations by year
- 2026: 434 · 2025: 551 · 2024: 549 · 2023: 522 · 2022: 535 · 2021: 465 · 2020: 270 · 2019: 5
- FWCI
- 268.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Eisai
- Japan Society for the Promotion of Science (17H01590, 17K19718)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- cetuximab, head and neck squamous cell carcinoma, recurrent or metastatic cancer, PD-L1 expression, PD-L1 combined positive score, immune checkpoint inhibitors, overall survival, progression-free survival, non-inferiority, p16 status, treatment safety
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Squamous Cell Carcinoma of Head and Neck, Progression-Free Survival, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
